Androstenedione
Androstenedione (4-Androstenedione) is a steroid which serves as a major precursor for testosterone and estrone. It is produced from 17-hydroxyprogesterone and dehydroepiandrosterone (DHEA) mainly by adrenal glands and is at least partly influenced by ACTH. It is also produced by the testes and ovaries independently of ACTH.
Its clinical interest derives from the fact that it is often elevated in cases of abnormal hair growth and virilization. Plasma levels increase steadily from about the seventh year of life and then gradually decline after the third decade. Androstenedione exhibits a diurnal variation being highest in the morning, and also a cyclical variation during the menstrual cycle, being highest near midcycle. Androstenedione is increased in hirsutism, including Stein-Leventhal syndrome, ovarian hyperplasia, congenital adrenal hyperplasia, Cushing syndrome, and in ectopic adrenocorticotropic hormone (ACTH) producing tumors.
Androstenedione plasma level might also be elevated in pregnancy.
Androstendione is useful in the differential diagnosis and monitoring of premature adrenanarche, congenital adrenal hyperplasia and hyperandrogenism. Early adrenarche does not correlate with early puberty, decreased height or phenotypic androgenization in males. Girls may show increased risk of polycystic ovarian disease. Males usually show no symptoms, but may convert androstendione to estrogen and consequently experience gynecomastia. Most modest increases of androstendione are of uncertain origin, but many of the markedly elevated cases are due to androstendione-secreting tumors arising within the adrenal glands or gonads. Testing for androstendione has become preferred for monitoring glucocorticoid therapy of congenital adrenal hyperplasia; this is due to the fact that it is a better reflection of disease control than 17-hydroxyprogesterone or another androgen.
- Differential diagnosis of hyperandrogenism
- Evaluation of androgen production in hirsutism in females
- As an aid in diagnosis of ovarian hyperplasia
- As an aid in diagnosis of adrenal hyperplasia
- As an aid in diagnosis of Cushing syndrome
- Evaluation of premature adrenarche
- Evaluation of gynecomastia
Increased in:
- Hyperandrogenism with increased adrenal or gonadal androgen production
- Hirsutism (female)
- Ovarian stromal hyperplasia
- Polycystic ovary syndrome, some cases
- Congenital adrenal hyperplasia
- Androgen-secreting adrenal or a gonadal tumor
- Ectopic ACTH producing tumors
- Cushing syndrome
- Osteoporosis in females
Both androstendione and testosterone should be measured to monitor therapy in congenital adrenal hyperplasia, the primary goal being to normalize ACTH and sex steroid levels if possible.
Androstendione supplements will raise serum levels of this hormone. Also, certain drugs that can increase activity of liver enzymes, drugs that often affect lipid metabolism and of course other hormones, can all affect androstendione levels, most commonly decreasing the levels.
| Population / Age Group | ng/dL | nmol/L |
| Cord | 30–150 | 1.0–5.0 |
| Premature | 80–446 | 2.8–15.6 |
| Newborn (1–7 days) | 20–290 | 0.7–10.1 |
| Prepubertal | 8–50 | 0.3–1.7 |
| Puberty (10–17 years) | 8–240 | 0.3–8.4 |
| Adult Male | 75–205 | 2.6–7.2 |
| Adult Female | 85–275 | 3.0–9.6 |
Serum (SST), Plasma EDTA (Lavende) or Heparin (Green)
Stability
- Ambient: 14 days
- Refrigerated: 28 days
- Frozen: 12 months
- J Clin Endocrinol Metab. 1974 Aug;39(2):340-6. [PMID: 4278727]
- Clin Lab. 2005;51(11-12):625-32. [PMID: 16329620]
- Hum Reprod Update. 2008 Jan-Feb;14(1):73-82. [PMID: 18056750]
- Fertil Steril. 2002 Apr;77 Suppl 4:S3-5. [PMID: 12007895]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757